Novasenta Completes $40 million Series A to Advance Novel Cancer Therapeutics
/PRNewswire/ -- Novasenta Inc., a startup biotechnology company focused on the discovery and validation of novel targets to develop cancer therapies, today...
Source: prnewswire.com